



Intellia Therapeutics to Present at November Healthcare Investor Conferences

November 2, 2017

CAMBRIDGE, Mass., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will present at the following upcoming healthcare conferences in November:

Tuesday, November 7, 2017

Credit Suisse 26th Annual Healthcare Conference

Who: Tom Barnes, Ph.D., Senior Vice President, Innovation Sciences

Location: Scottsdale, Arizona

Presentation Time: 9:45am MST (11:45am EST)

Wednesday, November 15, 2017

Jefferies London Healthcare Conference

Who: John Leonard, M.D., Executive Vice President, R&D

Location: London, United Kingdom

Presentation Time: 8:40am GMT (2:40am EST)

Thursday, November 30, 2017

Barclays Gene Editing/Therapy Summit

Who: Nessian Bermingham, Ph.D., Chief Executive Officer and Founder

Location: New York, New York

Presentation Time: 1:40pm EST

A live webcast of Intellia's presentations will be accessible through the Events and Presentations page of the Investor Relations section of the company's website at www.intelliatrix.com. To access the webcasts, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Intellia's website for 14 days following each conference.

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company focused on the development of proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatrix.com; Follow us on Twitter @intelliaweets

Investor Contact:

Lindsey Trickett

Vice President, Investor Relations

+1 857-285-6211

lindsey.trickett@intelliatrix.com

Media Contact:

Jennifer Mound Smoter

Senior Vice President, External Affairs &

Communications

1 857-706-1071

jenn.smoter@intelliatrix.com

Source: Intellia Therapeutics, Inc.